Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Surgical Treatment of Gastroesophageal Junction Cancer

  • Hashimoto, Tadayoshi (Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine) ;
  • Kurokawa, Yukinori (Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine) ;
  • Mori, Masaki (Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine) ;
  • Doki, Yuichiro (Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine)
  • Received : 2018.08.23
  • Accepted : 2018.09.02
  • Published : 2018.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Although the incidence of gastroesophageal junction (GEJ) adenocarcinoma has been increasing worldwide, no standardized surgical strategy for its treatment has been established. This study aimed to provide an update on the surgical treatment of GEJ adenocarcinoma by reviewing previous reports and propose recommended surgical approaches. The Siewert classification is widely used for determining which surgical procedure is used, because previous studies have shown that the pattern of lymph node (LN) metastasis depends on tumor location. In terms of surgical approaches for GEJ adenocarcinoma, a consensus was reached based on two randomized controlled trials. Siewert types I and III are treated as esophageal cancer and gastric cancer, respectively. Although no consensus has been reached regarding the treatment of Siewert type II, several retrospective studies suggested that the optimal treatment strategy includes paraaortic LN dissection. Against this background, a Japanese nationwide prospective trial is being conducted to determine the proportion of LN metastasis in GEJ cancers and to identify the optimal extent of LN dissection in each type.

Keywords

References

  1. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-1289. https://doi.org/10.1001/jama.1991.03460100089030
  2. Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the cancer incidence in five continents database. Int J Epidemiol 2001;30:1415-1425. https://doi.org/10.1093/ije/30.6.1415
  3. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007;17:2-9. https://doi.org/10.1016/j.semradonc.2006.09.003
  4. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007;8:545-553. https://doi.org/10.1016/S1470-2045(07)70172-9
  5. DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol 2006;13:12-30. https://doi.org/10.1245/ASO.2005.12.025
  6. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831. https://doi.org/10.1056/NEJM199903183401101
  7. Kauppila JH, Lagergren J. The surgical management of esophago-gastric junctional cancer. Surg Oncol 2016;25:394-400. https://doi.org/10.1016/j.suronc.2016.09.004
  8. Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 8th ed. Hoboken (NJ): Wiley-Blackwell, 2017.
  9. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998;85:1457-1459. https://doi.org/10.1046/j.1365-2168.1998.00940.x
  10. Misumi A, Murakami A, Harada K, Baba K, Akagi M. Definition of carcinoma of the gastric cardia. Langenbecks Arch Chir 1989;374:221-226. https://doi.org/10.1007/BF01359557
  11. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011;14:101-112. https://doi.org/10.1007/s10120-011-0041-5
  12. Japan Esophageal Society. Japanese Classification of Esophageal Cancer. 2nd ed. Tokyo: Japan Esophageal Society, 2008.
  13. Grotenhuis BA, Wijnhoven BP, van Marion R, van Dekken H, Hop WC, Tilanus HW, et al. The sentinel node concept in adenocarcinomas of the distal esophagus and gastroesophageal junction. J Thorac Cardiovasc Surg 2009;138:608-612. https://doi.org/10.1016/j.jtcvs.2008.11.061
  14. Rudiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000;232:353-361. https://doi.org/10.1097/00000658-200009000-00007
  15. Kurokawa Y, Hiki N, Yoshikawa T, Kishi K, Ito Y, Ohi M, et al. Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction. Surgery 2015;157:551-555. https://doi.org/10.1016/j.surg.2014.08.099
  16. Yoshikawa T, Takeuchi H, Hasegawa S, Nozaki I, Kishi K, Ito S, et al. Theoretical therapeutic impact of lymph node dissection on adenocarcinoma and squamous cell carcinoma of the esophagogastric junction. Gastric Cancer 2016;19:143-149. https://doi.org/10.1007/s10120-014-0439-y
  17. Yamashita H, Seto Y, Sano T, Makuuchi H, Ando N, Sasako M, et al. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer 2017;20 Suppl 1:69-83. https://doi.org/10.1007/s10120-016-0663-8
  18. Nunobe S, Ohyama S, Sonoo H, Hiki N, Fukunaga T, Seto Y, et al. Benefit of mediastinal and para-aortic lymph-node dissection for advanced gastric cancer with esophageal invasion. J Surg Oncol 2008;97:392-395. https://doi.org/10.1002/jso.20987
  19. Matsumoto S, Takayama T, Wakatsuki K, Enomoto K, Tanaka T, Migita K, et al. Surgical outcomes for cancer at the gastroesophageal junction. Am Surg 2012;78:1285-1291.
  20. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662-1669. https://doi.org/10.1056/NEJMoa022343
  21. Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007;246:992-1000. https://doi.org/10.1097/SLA.0b013e31815c4037
  22. Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006;7:644-651. https://doi.org/10.1016/S1470-2045(06)70766-5
  23. Kurokawa Y, Sasako M, Sano T, Shibata T, Ito S, Nashimoto A, et al. Functional outcomes after extended surgery for gastric cancer. Br J Surg 2011;98:239-245. https://doi.org/10.1002/bjs.7297
  24. Kurokawa Y, Sasako M, Sano T, Yoshikawa T, Iwasaki Y, Nashimoto A, et al. Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg 2015;102:341-348. https://doi.org/10.1002/bjs.9764
  25. Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 1995;82:346-351. https://doi.org/10.1002/bjs.1800820321
  26. Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg 2011;254:274-280. https://doi.org/10.1097/SLA.0b013e3182263911
  27. Fujitani K, Miyashiro I, Mikata S, Tamura S, Imamura H, Hara J, et al. Pattern of abdominal nodal spread and optimal abdominal lymphadenectomy for advanced Siewert type II adenocarcinoma of the cardia: results of a multicenter study. Gastric Cancer 2013;16:301-308. https://doi.org/10.1007/s10120-012-0183-0
  28. Yabusaki H, Nashimoto A, Matsuki A, Aizawa M. Comparison of the surgical treatment strategies for Siewert type II squamous cell carcinoma in the same area as esophagogastric junction carcinoma: data from a single Japanese high-volume cancer center. Surg Today 2014;44:1522-1528. https://doi.org/10.1007/s00595-013-0773-4
  29. Mine S, Kurokawa Y, Takeuchi H, Kishi K, Ito Y, Ohi M, et al. Distribution of involved abdominal lymph nodes is correlated with the distance from the esophagogastric junction to the distal end of the tumor in Siewert type II tumors. Eur J Surg Oncol 2015;41:1348-1353. https://doi.org/10.1016/j.ejso.2015.05.004
  30. Hosokawa Y, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kato Y, et al. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann Surg Oncol 2012;19:677-683. https://doi.org/10.1245/s10434-011-1983-x
  31. Pedrazzani C, de Manzoni G, Marrelli D, Giacopuzzi S, Corso G, Minicozzi AM, et al. Lymph node involvement in advanced gastroesophageal junction adenocarcinoma. J Thorac Cardiovasc Surg 2007;134:378-385. https://doi.org/10.1016/j.jtcvs.2007.03.034
  32. Cense HA, Sloof GW, Klaase JM, Bergman JJ, van Hemert FJ, Fockens P, et al. Lymphatic drainage routes of the gastric cardia visualized by lymphoscintigraphy. J Nucl Med 2004;45:247-252.
  33. de Manzoni G, Pedrazzani C, Di Leo A, Bonfiglio M, Tasselli S, Guglielmi A, et al. Metastases to the paraaortic lymph nodes in adenocarcinoma of the cardia. Eur J Surg 2001;167:413-418. https://doi.org/10.1080/110241501750243743
  34. Hasegawa S, Yoshikawa T, Rino Y, Oshima T, Aoyama T, Hayashi T, et al. Priority of lymph node dissection for Siewert type II/III adenocarcinoma of the esophagogastric junction. Ann Surg Oncol 2013;20:4252-4259. https://doi.org/10.1245/s10434-013-3036-0
  35. Mine S, Sano T, Hiki N, Yamada K, Nunobe S, Yamaguchi T. Lymphadenectomy around the left renal vein in Siewert type II adenocarcinoma of the oesophagogastric junction. Br J Surg 2013;100:261-266. https://doi.org/10.1002/bjs.8967
  36. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-462. https://doi.org/10.1056/NEJMoa0707035

Cited by

  1. Aggressive Graphic/Surgical R0 Resection and Jejunal Interposition with Preservation of Mesojejunal Autonomic Nerves in Patients with Stage IV Esophagogastric Junction Adenocarcinoma: A Report of 3 Ca vol.20, pp.None, 2019, https://doi.org/10.12659/ajcr.913960
  2. Should Multidisciplinary Treatment Differ for Esophageal Adenocarcinoma Versus Esophageal Squamous Cell Cancer? vol.26, pp.4, 2018, https://doi.org/10.1245/s10434-019-07162-9
  3. Surgical principles for optimal treatment of esophagogastric junction adenocarcinoma vol.3, pp.4, 2019, https://doi.org/10.1002/ags3.12268
  4. Feasibility and usability of real-time intraoperative quantitative fluorescent-guided perfusion assessment during resection of gastroesophageal junction cancer vol.405, pp.2, 2018, https://doi.org/10.1007/s00423-020-01876-1
  5. Comparison of the 8th UICC staging system for esophageal and gastric cancers in Siewert type II junctional adenocarcinomas vol.46, pp.4, 2018, https://doi.org/10.1016/j.ejso.2019.12.011
  6. Sites of distant metastases and the cancer-specific survival of metastatic Siewert type II esophagogastric junction adenocarcinoma: a population-based study vol.14, pp.6, 2018, https://doi.org/10.1080/17474124.2020.1760839
  7. Treatment Alternatives for Recurrent Esophagogastric Junction Adenocarcinoma: Case Report of an Ileocolonic Reconstruction and Literature Review vol.12, pp.8, 2020, https://doi.org/10.7759/cureus.9504
  8. Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors : A Prospective Nationwide Multicenter Study vol.274, pp.1, 2018, https://doi.org/10.1097/sla.0000000000003499
  9. Association of Common Medications and the Risk of Early-Onset Gastric Cancer: A Population-Based Matched Study vol.2021, pp.None, 2021, https://doi.org/10.1155/2021/2670502